Factors Associated with Prolonged SARS-CoV-2 Viral Positivity in an Italian Cohort of Hospitalized Patients
- PMID: 39057109
- PMCID: PMC11275323
- DOI: 10.3390/diseases12070138
Factors Associated with Prolonged SARS-CoV-2 Viral Positivity in an Italian Cohort of Hospitalized Patients
Abstract
Clinical or microbiological factors potentially associated with prolonged COVID-19 PCR positivity are still poorly underexplored, but they could be of importance for public-health and clinical reasons. The objective of our analysis is to explore demographic, clinical, and microbiological factors potentially associated with a prolonged positivity to SARS-CoV-2 among 222 hospitalized patients. Prolonged detection positivity for SARS-CoV-2 RNA in swap samples, defined as positivity more than 21 days, was the outcome of interest. The 56 cases with a prolonged positivity to SARS-CoV-2 were matched for age and sex with 156 controls. The cases reported a significantly higher presence of diabetes mellitus, autoimmune diseases, chronic kidney diseases, and acute coronary syndrome. Moreover, the viral load was significantly higher in a period of prolonged positivity compared to a normal period. In the multivariable analysis, the presence of autoimmune diseases and chronic kidney disease were significantly associated with an increased risk of prolonged positivity as well as medium viral load or high viral load, i.e., low Ct value ≤ 30 indicating high viral load. The results of this study confirmed that in a large population of hospitalized patients with COVID-19 manifestations, the prolonged positivity of SARS-CoV-2 detection with nasopharyngeal swab was mainly related to autoimmune diseases, chronic kidney disease, and to baseline viral load.
Keywords: COVID-19; autoimmune disease; chronic kidney disease; prolonged positivity; viral load.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2. Trials. 2021. PMID: 33685502 Free PMC article.
-
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z. Trials. 2020. PMID: 32513289 Free PMC article.
-
Cycle threshold values of SARS-CoV-2 RNA in conjunctival swabs and nasopharyngeal secretions: a comparative study from a tertiary care center in India.Int Ophthalmol. 2024 Feb 8;44(1):29. doi: 10.1007/s10792-024-02976-3. Int Ophthalmol. 2024. PMID: 38329577
-
Evaluation of the SARS-CoV-2 positivity ratio and upper respiratory tract viral load among asymptomatic individuals screened before hospitalization or surgery in Flanders, Belgium.PLoS One. 2021 Nov 11;16(11):e0259908. doi: 10.1371/journal.pone.0259908. eCollection 2021. PLoS One. 2021. PMID: 34762704 Free PMC article.
-
[SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].Mikrobiyol Bul. 2020 Jul;54(3):497-509. doi: 10.5578/mb.69839. Mikrobiyol Bul. 2020. PMID: 32755524 Review. Turkish.
References
-
- Sung A., Bailey A.L., Stewart H.B., McDonald D., Wallace M.A., Peacock K., Miller C., Reske K.A., O’Neil C.A., Fraser V.J., et al. Isolation of SARS-CoV-2 in Viral Cell Culture in Immunocompromised Patients with Persistently Positive RT-PCR Results. Front. Cell Infect. Microbiol. 2022;12:804175. doi: 10.3389/fcimb.2022.804175. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous